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Fig 1. A, Lichen planus pigmentosus and frontal fibrosing alopecia. Diffuse hyperpigmenta-
tion of upper chest, neck, and cheeks with loss of eyebrow hair and recession of frontal
hairline. B, A punch biopsy demonstrates an atrophic lichenoid dermatitis with many
perijunctional necrotic keratinocytes and melanophages, as is typical of lichen planus
pigmentosus. C, Transverse sectioning of a punch biopsy of the scalp demonstrates concentric
perifollicular fibrosis, limited compound follicle formation, and a modest lymphocytic infiltrate.
This combination is diagnostic of a lymphocyte-mediated primary cicatricial alopecia, and
clinicopathologic correlation favored a diagnosis of frontal fibrosing alopecia.
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carcinoma of the skin with anastrozole
To the Editor: An 80-year-old woman with a recur-
rent primary mucinous carcinoma of the scalp
presented for Mohs surgery (Fig 1). After several
stages of Mohs surgery, the tumor was deemed
unresectable because of its depth and the extent of
bone involvement. Clinical exam, computed tomog-
raphy, positron emission tomography (PET) scan,
and lymph node biopsy revealed mucinous carci-
noma in the cervical, hilar, and mediastinal lymph
nodes, as well as lung parenchymal involvement.
The tumor cells were strongly positive for estrogen
receptors (ERs), negative for progesterone receptors
(PRs), GCDFP, and CK20. The patient underwent
local radiation of the scalp and neck over 6 months.
The patient was also started on anastrozole
(Arimidex), an aromatase inhibitor, 1 mg daily due
to the tumor cells’ strong ER positivity. Follow-up
PET scan showed no hypermetabolic focus on
the scalp, neck, or chest. Five years after diag-
nosis, no signs of scalp recurrence or metastatic
progression can be detected on physical exam
or PET scan. Mammography and colonoscopy
results continue to be negative. She continues to
Fig 1. Hematoxylin-eosin stain of primary mucinous
carcinoma of the skin.
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e28 Letterstake and tolerate anastrozole therapy, which was
complicated only by a slight decrease in bone
density that was stabilized with weekly alendronate
(Fosamax).
Mucinous carcinoma of the skin can be locally
invasive and approximately 30% recur after excision,
but has low rate of regional metastasis through
lymphatic spread (9.6%) and only 2% of cases are
fatal.1 It is recommended that patients undergo
wide local excision, but recent data have shown
Mohs micrographic surgery to be valuable in
establishing clear margins and decreased recur-
rence.1,2 Unfortunately, as in our case, the tumor is
not completely resectable even using Mohs micro-
graphic technique.
Primary mucinous carcinoma of the skin (PMCS)
can appear clinically and histologically identical to
metastatic adenocarcinomas from other sites such as
lung, breast, and colon.3 It is important to distinguish
between the 2 because of the differences in prog-
nosis and treatment. Therefore, the use of imaging
studies, immunohistochemical staining of biopsied
specimens, and collaboration with oncology staff is
often required. Unfortunately, PMCS and cutaneous
metastases of mucinous breast adenocarcinoma can
be immunohistochemically identical, making differ-
entiation between the 2 impossible without clinical
identification of a primary breast carcinoma.
Similarities between ER-positive breast carcinomasand ER-positive PMCS, as in our case, suggest that
aromatase inhibitors may be beneficial in PMCS.
There are 2 major risk factors seen with aromatase
inhibitors that should be carefully monitored: oste-
oporosis with fracture4 and cardiovascular events
due to increased lipids.5
In order to prevent local invasion, recurrence, and
the rare metastasis, the antiestrogenic medications
may be beneficial in PMCS given its similarities to
primary mammary mucinous carcinoma and the
strong ER positivity found in these tumors.5 We
suggest testing for ER/PR expression in PMCS and
advocate for the potential use of aromatase inhibitor
therapy in advanced disease.
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